Compare Prudential PLC (PUK) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs Viatris Inc — how do they compare? Prudential PLC trades at $27.1 (market cap $34.05B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Prudential PLC is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| PUK | VTRS | |
|---|---|---|
Market Cap | $34.05B | $19.09B |
Sector | Financials | Health |
52-Week High | $33.61 | $17.86 |
52-Week Low | $24.98 | $9.49 |
Enterprise Value | $33.60B | $31.21B |
Dividend Yield | 2.03% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential (PUK) trades at $27.42, down 1.19% over 24 hours, with a bearish technical signal from moving averages. Recent earnings show mixed quarterly results, with Q2 2026 EPS missing expectations. The company reported strong revenue growth to $27.39B in 2025 and a net income margin of 14.52%, supported by a low P/E of 9.64. Recent news highlights management's focus on reshaping the business and expanding in Asian and African markets, though shares faced pressure from China tax policy concerns in August 2026.
The outlook for PUK is cautiously optimistic, with solid fundamentals and analyst support offset by technical weakness and geopolitical risks. Investment opportunities include attractive valuation and strategic growth initiatives, while risks involve earnings volatility and regulatory changes in key markets like China. Investors should weigh the strong ROE of 19.24% against recent price declines and bearish momentum indicators.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
